- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01735344
Bioequivalence Study of Lisinopril Tablets 40 mg Under Fed Condition
A Randomized, Balanced, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study of Lisinopril Tablets 40 mg With Zestril® (Lisinopril) 40 mg Tablets in Normal, Healthy, Adult, Male and Female Human Subjects Under Fed Conditions.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objective of this pivotal study was to assess the bioequivalence between Test Product: Lisinopril Tablets 40 mg of Ipca Laboratories Limited, India and the corresponding Reference Product: Zestril® (Lisinopril) 40 mg Tablets of AstraZeneca Pharmaceuticals LP USA, under fed condition in normal, healthy, adult, male and female human subjects in a randomized crossover study.
The study was conducted with 40 healthy adult subjects. In each study period, a single 40 mg dose of either test or reference was administered to the subjects as per the randomization schedule in each study period with about 240 mL of water at ambient temperature in sitting position.
The duration of the clinical phase was approximately 18 days including washout period of 14 days between administrations of study drug in each study period.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Gujarat
-
Navi-Mumbai, Gujarat, India
- Accutest Research Lab (I) Pvt. Ltd.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and non pregnant female human subjects, age in the range of 18 - 45 years.
- Body weight within ± 15% of ideal weight as related to height and body frame according to Life Insurance Corporation (LIC) Chart.
- Subjects with normal findings as determined by baseline history, physical examination and vital sign examination (blood pressure, pulse rate, respiration rate and axillary temperature).
- Subjects with clinically acceptable findings as determined by haemogram, biochemistry, urinalysis and 12 lead ECG.
- Willingness to follow the protocol requirements especially abstaining from xanthine containing food or beverages (chocolates, tea, coffee or cola drinks) or grapefruit juice, any alcoholic products, the use of cigarettes and tobacco products for 48 hours prior to dosing until after the last blood sample collection in each study period and adherence to food, fluid and posture restrictions.
- No history of significant alcoholism.
- No history of drug abuse (benzodiazepines and barbiturates) for the last one month and other illegal drugs for the last 6 months.
- Non-smokers were included.
Exclusion Criteria:
- Known history of hypersensitivity to Lisinopril or related drugs.
- Requiring medication for any ailment having enzyme-modifying activity in the previous 28 days, prior to dosing day.
- Subjects who have taken prescription medications or over-the-counter products (including vitamins and minerals) within 14 days prior to administration of Investigational Product.
- Any medical or surgical conditions, which might significantly interfere with the functioning of gastrointestinal tract, blood-forming organs etc.
- History of cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological, metabolic, haematological, gastrointestinal, endocrine, immunological or psychiatric diseases.
- Participation in a clinical drug study or bioequivalence study 90 days prior to present study.
- History of malignancy or other serious diseases.
- Blood donation 90 days prior to the commencement of the study.
- Subjects with positive HIV tests, HBsAg or Hepatitis-C tests.
- Found positive in breath alcohol test.
- Found positive in urine test for drug abuse.
- History of problem in swallowing.
- Any contraindication to blood sampling.
- Found positive serum Beta- hCG (Human Chorionic Gonadotropin) test.
- Lactating women (currently breast feeding).
- Female subjects not confirming to using birth control measures, from the date of screening until the completion of the study. Abstinence, barrier methods (condom, diaphragm, etc.) were acceptable. Use of hormonal contraceptives either oral or implants.
- Female subjects whose menstruation cycle coincided with the study periods.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lisinopril Tablets 40 mg
Lisinopril Tablets 40 mg of Ipca Laboratories Limited, India
|
40 mg tablet once a day
Other Names:
|
Active Comparator: Zestril® (Lisinopril) 40 mg Tablets
Zestril® (Lisinopril) 40 mg Tablets of AstraZeneca Pharmaceuticals LP USA
|
40 mg tablet once a day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax
Time Frame: 2 months
|
Sampling Hours: Pre-dose and at 1.00, 2.00, 3.00, 4.00, 5.00, 6.00, 6.25, 6.50, 6.75, 7.00, 7.25, 7.50, 7.75, 8.00, 8.50, 9.00, 10.00, 12.00, 16.00, 24.00, 48.00 and 72.00 hrs post dose.
|
2 months
|
AUC
Time Frame: 2 months
|
Sampling Hours: Pre-dose and at 1.00, 2.00, 3.00, 4.00, 5.00, 6.00, 6.25, 6.50, 6.75, 7.00, 7.25, 7.50, 7.75, 8.00, 8.50, 9.00, 10.00, 12.00, 16.00, 24.00, 48.00 and 72.00 hrs post dose.
|
2 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Ipca/ARL-10/385
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fed
-
IPCA Laboratories Ltd.Completed
-
IPCA Laboratories Ltd.Completed
-
IPCA Laboratories Ltd.Completed
-
IPCA Laboratories Ltd.Completed
-
IPCA Laboratories Ltd.Completed
-
Dr. Reddy's Laboratories LimitedCompleted
-
Umeå UniversityUniversity of California; Mead Johnson NutritionActive, not recruitingHealth of Formula-fed Children | Infant Infections in Formula-fed Children | Iron Status of Formula-fed ChildrenSweden
-
Dr. Reddy's Laboratories LimitedCompleted
-
IPCA Laboratories Ltd.Completed
-
IPCA Laboratories Ltd.Completed
Clinical Trials on Lisinopril Tablets 40 mg
-
IPCA Laboratories Ltd.Completed
-
SandozCompleted
-
Eisai Inc.CompletedPurpura, Thrombocytopenic, Idiopathic | Chronic Thrombocytopenia | Acute Idiopathic Thrombocytopenic PurpuraNetherlands
-
SandozCompleted
-
Valenta Pharm JSCCompletedInfluenza, Human | Common Cold | Acute Respiratory InfectionRussian Federation
-
Luye Pharma Group Ltd.Shandong Luye Pharmaceutical Co., Ltd.Completed
-
Par Pharmaceutical, Inc.PharmaKinetics Laboratories Inc.CompletedTo Determine Bioequivalence Under Fed ConditionsUnited States
-
Dexa Medica GroupCompleted
-
Mylan Pharmaceuticals IncCompletedHealthyUnited States
-
Teva Pharmaceuticals USACompleted